StockTipsArenaBeta

SELL Gland Pharma Limited — Goldman Sachs

SELLGland Pharma Limited
Gland Pharma share price target & all analyst calls

byGoldman SachsHorizon: NA (inferred 1 year)9 Nov 2026via ET Now (Live)

Entry₹3,147Inferred
Target₹2,750
Total upside +12.62%
Stop lossNot given
CMP₹3,334.11d ago
Active-5.95%+17.52%upside left 12 mo left
Follow Goldman Sachs for new calls(100% target hit, 47 closed calls)Get alertsWatch GLAND for new buy/sell callsGet alertsSee 10 other Long-term calls on GLANDSee 272 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.

As of 15 Nov, 3:34 am IST
3 supporting10 neutral23 opposing
Supports the SELL call (3)

1 other SEBI-registered advisor has an active long-term SELL call on this stock, issued in the last 14 days

Advisor consensus · same horizon·9 Nov · 5d ago

Neutral / worth noting (10)

Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·6 Nov · 1w ago

(opens in new tab)

Gland Pharma USFDA Inspection Dundigal Facility 2026

NewsGoogle News·23 Oct · 3w ago

(opens in new tab)
Weighs against the SELL call (23)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·13 Nov · yesterday

6 other SEBI-registered advisors have active long-term BUY calls on this stock, with 4 issued in the last 14 days

Advisor consensus · same horizon·12 Nov · 2d ago

Gland Pharma shares jump 7% to 52-week high; Nomura sees re-rating but Citi says 'sell'

NewsCnbc-Tv18·9 Nov · 5d ago

(opens in new tab)

Gland Pharma shares hit 52-week high; jump 7% despite market sell-off | Will rally continue after 93% YTD rise?

NewsLivemint·9 Nov · 5d ago

(opens in new tab)

Gland Pharma Q2 Results: Net profit jumps 58% on strong business execution, CDMO revenue up 31%

NewsCnbc-Tv18·6 Nov · 1w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Gland Pharma

All analyst calls on Gland Pharma

More from Goldman Sachs

Every call and its outcome